Brokerages Set Gemphire Therapeutics Inc. (GEMP) Price Target at $24.60

Shares of Gemphire Therapeutics Inc. (NASDAQ:GEMP) have earned a consensus rating of “Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $24.60.

Several research analysts recently commented on GEMP shares. Canaccord Genuity reiterated a “buy” rating on shares of Gemphire Therapeutics in a research note on Friday, October 13th. Zacks Investment Research lowered shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 17th. HC Wainwright started coverage on shares of Gemphire Therapeutics in a research note on Thursday, August 31st. They set a “buy” rating and a $21.00 price objective for the company. Finally, Roth Capital started coverage on shares of Gemphire Therapeutics in a research note on Thursday, October 19th. They set a “buy” rating and a $30.00 price objective for the company.

Gemphire Therapeutics (NASDAQ:GEMP) traded up $0.48 during midday trading on Friday, hitting $8.12. 41,096 shares of the company traded hands, compared to its average volume of 64,484. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.17 and a quick ratio of 4.17. Gemphire Therapeutics has a 1 year low of $7.20 and a 1 year high of $21.59.

Gemphire Therapeutics (NASDAQ:GEMP) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.14). research analysts forecast that Gemphire Therapeutics will post -3.31 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in GEMP. Bamco Inc. NY purchased a new stake in Gemphire Therapeutics during the 3rd quarter worth approximately $2,709,000. Northpointe Capital LLC purchased a new stake in Gemphire Therapeutics during the 2nd quarter worth approximately $3,472,000. Comerica Bank purchased a new stake in Gemphire Therapeutics during the 3rd quarter worth approximately $850,000. GM Advisory Group Inc. purchased a new stake in Gemphire Therapeutics during the 2nd quarter worth approximately $457,000. Finally, Vanguard Group Inc. grew its position in Gemphire Therapeutics by 137.6% during the 2nd quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock worth $399,000 after purchasing an additional 17,892 shares during the last quarter. 32.11% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Brokerages Set Gemphire Therapeutics Inc. (GEMP) Price Target at $24.60” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://sportsperspectives.com/2017/12/14/brokerages-set-gemphire-therapeutics-inc-gemp-price-target-at-24-60.html.

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Analyst Recommendations for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply